About 85% to 90% of the cases of age-related macular degeneration (AMD) are the “dry” (atrophic) type.
People with this type of AMD may have good central vision (20/40 or better) but substantial functional limitations that may include fluctuating vision, difficulty reading because of limited central vision, or limited vision in mesopic conditions, according to the Age-Related Macular Degeneration Foundation (www.macula.org), a nonprofit group that not only funds research into AMD, but provides education for people affected by the disease.
To date, there are no approved pharmacologic treatments for the dry form, but there are several studies under way. Some of the studies listed on ClinicalTrials.gov:
• Chinese researchers are evaluating retinal pigment transplantation with cells derived from human embryonic stem cells in a phase I/II study (NCT03046407). This study intends to transplant human embryonic stem cells derived retinal pigment epithelia into subretinal space of patients to treat dry age-related macular degeneration (dry-AMD).
Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the safety and efficacy of RPE transplants to treat dry AMD.